The drug, JTX-1811, is designed to work by depleting certain T cells that suppress the immune system's response to tumors. A regulatory filing to begin clinical trials is expected in the first half of next year.
The biotech startup with a focus on cancer immunotherapy priced its initial public offering at $16 per share, well beyond the $13-$15 range initially projected.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Cambridge biotech Jounce Therapeutics is attempting a sort of one-stop cancer immunotherapy shop – using proprietary in-house diagnostics to inform its drug development process. Jounce just raised a hefty $56 million Series B, with plans to move its lead monoclonal antibody program into the clinic. But, interestingly, it’s also using the funding to build out “an atlas of human cancers,” CEO Rich Murray […]